XELOX plus fruquintinib and sintilimab for stomach cancer with liver or lymph node spread
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of chemotherapy (XELOX), a targeted therapy (fruquintinib), and an immunotherapy (sintilimab) to shrink stomach cancer that has spread only to the liver or retroperitoneal lymph nodes. The goal is to make the cancer removable by surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- You have HER2-negative or HER2-unknown stomach or gastroesophageal junction cancer that has come back or spread to only the liver or retroperitoneal lymph nodes (up to 5 spots, each less than 5 cm).
- You have not had prior treatment with a VEGFR-targeted drug or a PD-1/PD-L1 checkpoint inhibitor.
- You are able to swallow pills, have no active bleeding, and have good organ function (heart, liver, kidneys, bone marrow).
- You do not have other cancers (except certain early-stage ones), high blood pressure that is hard to control, serious heart conditions, autoimmune diseases, or active infections like hepatitis B or C.
- You have not had blood clots or strokes in the last 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy (XELOX), an immunotherapy drug (Sintilimab), and hyperbaric oxygen therapy for people with advanced or metastatic stomach or gastroesophageal junction cancer. The goal is to see if this triple therapy helps shrink or control the cancer better than current options.
This trial tests a combination of three drugs (fruquintinib, sintilimab, and CAPEOX chemotherapy) as a first treatment for advanced stomach or gastroesophageal cancer. The goal is to see if this combination helps slow or shrink the tumor.
This study tests a combination of three drugs (fruquintinib, trastuzumab, and XELOX chemotherapy) as the first treatment for people with advanced HER2-positive stomach or gastroesophageal junction cancer. The goal is to see if this combination is safe and effective for shrinking tumors.
This trial tests a combination of three drugs (BC001, Sintilimab, and XELOX chemotherapy) for people with advanced or metastatic HER-2 negative stomach cancer or cancer where the stomach meets the esophagus. The goal is to see if this combination works better than standard treatments.
This trial tests a combination of two targeted drugs (fruquintinib and sintilimab) plus standard chemotherapy for people with advanced stomach or gastroesophageal junction cancer that has not been treated before. The goal is to see if this combination can help shrink or control the cancer.
This phase 3 study compares two versions of a first-time treatment for HER2-negative advanced stomach or gastroesophageal cancer, both including immunotherapy (sintilimab). It looks for a safer or more effective way to slow cancer growth or improve outcomes.
Hear when a new Gastric Cancer/Gastroesophageal Junction Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.